Jul 1, 2012

In June, Baxter International Inc., announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B using Chatham’s gene therapy technology.

As part of the agreement, Baxter will use Chatham’s Biological Nano ParticlesTM (BNP), a recombinant adeno-associated virus-(rAAV) based gene therapy technology, to develop therapies for hemophilia B. Baxter has obtained global rights for the marketing and commercialization of the new treatment. While earlier clinical studies have shown the potential benefits of such a therapy, Baxter and Chatham intend to further investigate the experimental therapy through US-based clinical trials.

Source: RTTnews.com, June 5, 2012